Genetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban in patients with nonvalvular atrial fibrillation: A multicentre prospective cohort study.

Qian Xiang, Zhe Wang,Guangyan Mu,Qiufen Xie,Zhiyan Liu,Shuang Zhou,Hanxu Zhang,Zining Wang,Jie Jiang,Kun Hu,Yatong Zhang,Zinan Zhao,Dongdong Yuan,Liping Guo,Tingting Wu,Jinhua Zhang, Na Wang,Jing Xiang,Zhichun Gu,Jianjun Sun,Yimin Cui

Clinical and translational medicine（2023）

Cited 1|Views28

No score

Abstract

Peak anti-FXa level was associated with risk of bleeding events in patients with NVAF receiving rivaroxaban. SUSD3 rs76292544 was suggestively associated with 12-month bleeding events and five SNPs (NCMAP rs4553122, PRF1 rs885821, PRKAG2 rs12703159, rs13224758 and POU2F3 rs2298579) were suggestively associated with peak anti-FXa level.

Translated text

Key words

atrial fibrillation, bleeding, genetic polymorphism, pharmacodynamics, rivaroxaban

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined